# Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

> **NCT04637594** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 3 (actual)

## Conditions studied

- Locally Advanced Bladder Urothelial Carcinoma
- Locally Advanced Renal Pelvis Urothelial Carcinoma
- Locally Advanced Ureter Urothelial Carcinoma
- Locally Advanced Urethral Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Renal Pelvis Urothelial Carcinoma
- Metastatic Ureter Urothelial Carcinoma
- Metastatic Urethral Urothelial Carcinoma
- Metastatic Urothelial Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab
- **DRUG:** Atezolizumab
- **DRUG:** Durvalumab
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT04637594
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-27
- **Primary completion:** 2024-06-01
- **Final completion:** 2030-09
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04637594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04637594, "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04637594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*